Health Economics Policy and Law

Papers
(The TQCC of Health Economics Policy and Law is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Australia's Response to COVID-19100
Response to COVID-19: was Italy (un)prepared?53
France's response to the Covid-19 pandemic: between a rock and a hard place36
Need, demand, supply in health care: working definitions, and their implications for defining access35
United States response to the COVID-19 pandemic, January–November 202028
Going hard and early: Aotearoa New Zealand's response to Covid-1923
Unmasking a health care system: the Dutch policy response to the Covid-19 crisis22
The federal government and Canada's COVID-19 responses: from ‘we're ready, we're prepared’ to ‘fires are burning’15
Soft law and individual responsibility: a review of the Swedish policy response to COVID-1915
Belgium's response to the COVID-19 pandemic12
Any lessons to learn? Pathways and impasses towards health system resilience in post-pandemic times12
Ireland's takeover of private hospitals during the COVID-19 pandemic12
Past experiences with surprise medical bills drive issue knowledge, concern and attitudes toward federal policy intervention9
An application of PCA-DEA with the double-bootstrap approach to estimate the technical efficiency of New Zealand District Health Boards9
Understanding public procurement within the health sector: a priority in a post-COVID-19 world9
Do patients benefit from legislation regulating step therapy?8
Expanding health care coverage in Canada: a dramatic shift in the debate7
We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment6
Strengthening health system governance in Germany: looking back, planning ahead6
Learning lessons from the COVID-19 pandemic6
Physician behaviour, malpractice risk and defensive medicine: an investigation of cesarean deliveries6
Internal barriers to efficiency: why disinvestments are so difficult. Identifying and addressing internal barriers to disinvestment of health technologies5
(Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time5
Mandatory reporting legislation in Canada: improving systems for patient safety?5
Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals5
Just a question of time? Explaining non-take-up of a public health insurance program designed for undocumented immigrants living in France4
If you were a policymaker, which treatment would you disinvest? A participatory value evaluation on public preferences for active disinvestment of health care interventions in the Netherlands4
Exorcising the positivist ghost in the priority-setting machine: NICE and the demise of the ‘social value judgement’3
Why we need to face up to the ageing population?3
Trump v. The ACA3
The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies3
Health misinformation and freedom of expression: considerations for policymakers3
New governance of the digital health agency: a way out of the joint decision trap to implement electronic health records in Germany?3
0.017512083053589